26 December 2023 in Journal of Obstetrics and Gynaecology Research
10 October 2025 in Medicine
This study aimed to evaluate the predictive factors associated with the success of cervical cerclage, particularly focusing on postoperative cervical length and maternal serum procalcitonin levels. A cross-sectional retrospective study was conducted on 129 pregnant women who underwent cervical cerclage at a perinatal medical center. Patients were categorized into 3 groups: history-indicated (G1), ultrasound-indicated (G2), and rescue cerclage (G3). Preoperative and postoperative cervical length, procalcitonin, and C-reactive protein levels were analyzed in relation to pregnancy outcomes, including miscarriage, gestational age at delivery, and preterm premature rupture of membranes. Receiver operating characteristic curve analysis was performed to determine the optimal post-cerclage cervical length threshold for predicting successful pregnancy prolongation. Postoperative cervical length was significantly longer in patients with successful cerclage in the ultrasound-indicated (G2) and rescue cerclage (G3) groups ( P = .0151 and P < .0001, respectively). The optimal post-cerclage cervical length cutoff values for predicting birth after 28 weeks were 23.87 mm for G2 (area under the curve [AUC] = 0.78) and 22.18 mm for the combined G2 and G3 group (AUC = 0.71). Higher procalcitonin levels were associated with unsuccessful cerclage and poor pregnancy outcomes in G1 and G2. Preoperative cervical length was not a significant predictor of cerclage success (AUC = 0.52). Postoperative cervical length is a strong predictor of cerclage success, particularly in ultrasound-indicated and rescue cerclage cases. Maternal serum procalcitonin may serve as a novel biomarker for assessing cerclage prognosis. Serial cervical length measurements and biomarker assessments could improve clinical management in these patients. Further prospective studies are warranted to validate these findings.
23 January 2026 in Journal of Ultrasound in Medicine
24 October 2025 in Journal of Medicine and Palliative Care
Aims: Preeclampsia (PE) is a multisystem pregnancy disorder linked to abnormal placentation and significant maternal-fetal morbidity. Identifying reliable biomarkers that reflect placental dysfunction and disease severity remains clinically important. This study aimed to assess maternal serum levels of stathmin-1 (STMN-1), a regulator of cell proliferation and trophoblast invasion, in pregnancies complicated by PE with and without severe features, compared to healthy controls. Methods: This prospective, cross-sectional study included 81 pregnant women: 41 with PE (22 without severe features and 19 with severe features) and 40 normotensive healthy controls. Maternal serum STMN-1 levels were measured using a validated ELISA method. Clinical characteristics, perinatal outcomes, and laboratory findings were compared across groups. Results: STMN-1 levels were significantly lower in the PE group (5.99±3.37) than in controls (8.23±3.42)(p=0.004). Although not statistically significant (p=0.172), levels tended to be lower in PE without severe features compared to controls. STMN-1 levels were significantly lower in PE with severe features (4.88±2.96) than in PE without severe features (6.97±3.46, p=0.047) and controls (p=0.001). Conclusion: Maternal serum STMN-1 levels decrease in PE, particularly in severe cases. These findings suggest that STMN1 may serve as a useful biomarker for identifying and assessing the severity of PE. Further large-scale studies are needed to confirm its diagnostic and prognostic value.
10 April 2026 in Medicine
: We aimed to compare maternal serum prostasin levels between women with early-onset preeclampsia (PE) and healthy pregnant controls to establish pathophysiological differences. We also sought to evaluate the diagnostic performance of maternal serum prostasin as a potential biomarker for early-onset PE, including determination of optimal cutoff values for clinical application. This was a prospective case–control study including 43 pregnant women who were diagnosed with early-onset PE between 20 0/7 to 34 0/7 weeks of gestation from March to September 2022. Also, 45 healthy pregnant women were included in the control group. Demographic characteristics, complete blood count and biochemical parameters, and serum prostasin concentrations were documented. A receiver operating characteristic curve was generated to demonstrate the sensitivity and specificity of prostasin, and the optimal cutoff value was determined using the Youden index. The median maternal serum prostasin level was found to be significantly higher in the early-onset PE group (31.66 [27.12–51.00] ng/mL) compared to the control group (22.33 [16.03–25.89] ng/mL) with a P -value <.001. The area under the curve was found to be 0.820 ± 0.047 (95% CI: 0.729–0.912), indicating a statistically significant discriminative ability ( P < .001). The optimal cutoff value for maternal serum prostasin level was determined using the Youden index, with a threshold of ≥26.44 ng/mL corresponding to a sensitivity of 0.837 and a specificity of 0.778 for the diagnosis of early-onset PE. Based on the multivariate model results, a maternal serum prostasin value of >26.44 ng/mL increases the risk of early-onset PE by approximately 20-fold. Maternal serum prostasin levels are significantly elevated in early-onset preeclamptic mothers compared to the healthy controls. These findings suggest that prostasin may play a role in early-onset PE pathophysiology and could serve as a biomarker for its diagnosis.